Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2002-11-25 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec OAI AG english
Regulatory Filings Classification · 100% confidence The document is a short corporate news announcement dated November 25, 2002, detailing the extension of a discovery agreement between Evotec OAI AG and Solvay Pharmaceuticals. It discusses a business collaboration, not financial results, management changes, or regulatory filings like 10-K or ER. Since it is a general business update that doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), it falls best under the general 'Regulatory Filings' fallback category (RNS) as a miscellaneous corporate announcement, although it is primarily a press release. Given the options, RNS is the most appropriate catch-all for non-standard, non-financial regulatory news.
2002-11-25 English
Evotec OAI AG english
Regulatory Filings Classification · 100% confidence The document is a press release dated November 21, 2002, announcing a strategic agreement between Evotec OAI AG and Elixir Pharmaceuticals for drug discovery services. It details a business partnership and service contract, which falls under general corporate news or business development. Since there is no specific mention of earnings, capital structure changes, management changes, dividends, or regulatory filings like 10-K or IR, the most appropriate general category for a corporate news announcement that doesn't fit a more specific business event code is the fallback category, Regulatory Filings (RNS), as it represents miscellaneous corporate announcements distributed via news services (DGAP in this case). The document length (5386 chars) is substantial enough that it is the announcement itself, not just a notice of publication.
2002-11-21 English
Evotec OAI AG english
Earnings Release Classification · 100% confidence The document is titled 'Evotec OAI Q3 Results' and provides key financial metrics (revenues, operating loss, EBITDA, net loss) for the first 9 months and specifically mentions Q3 performance. It also discusses updated forecasts and cost-reduction actions. This structure—a brief announcement highlighting period-specific financial performance—is characteristic of an Earnings Release (ER). It is too brief and summary-focused to be a full Interim Report (IR) or Annual Report (10-K). Since it is an announcement of results, ER is the most appropriate classification. 9M 2002
2002-11-14 English
Evotec OAI AG english
M&A Activity Classification · 99% confidence The document is a 'Corporate-news announcement' dated November 7, 2002, detailing a specific business agreement between Evotec OAI AG and British Biotech plc regarding a medicinal chemistry optimization program. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It describes a strategic business development, partnership, or transaction. Since it is a general corporate news announcement about a business agreement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate announcements sent via news distribution services (like DGAP mentioned here). The length is moderate, but the content is purely informational news, not a formal report.
2002-11-07 English
Evotec OAI AG english
Regulatory Filings Classification · 95% confidence The document is a 'News Details' announcement sent by DGAP, titled 'Evotec OAI Successfully Completes Assay Development Programme with ALTANA'. It details the successful completion of a collaboration milestone and the integration of proprietary technology. This is a corporate news announcement regarding business operations and partnership success, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate news announcement that doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements distributed via news services.
2002-11-04 English
Evotec OAI AG english
Regulatory Filings Classification · 95% confidence The document is a 'Corporate-news announcement' dated October 31, 2002, detailing the extension of a technology partnership between Evotec OAI AG and Pfizer, including financial terms and technology transfer details. This type of announcement, which is a general corporate update about a business development (partnership extension, potential value, equity investment), does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (DIV, DVA), or management changes (MANG). It is a general regulatory announcement disseminated via a news service (DGAP). Since it is not a specific financial report, nor a proxy/remuneration document, the most appropriate fallback category for a general corporate news release that doesn't fit elsewhere is Regulatory Filings (RNS).
2002-10-31 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.